Bio-Path Holdings (BPTH) reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. BP1001-A downregulates growth factor receptor-bound protein 2 expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients.
Bio-Path has initiated animal studies to confirm the efficacy of BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. If successful, the company plans initiating a first-in-human Phase 1 clinical trial in 2025.
Shares of Bio-Path are up 65% in pre-market trade on Thursday.
For comments and feedback contact: [email protected]